Date: 2014-11-27
Type of information: Collaboration agreement
Compound: 3C23K antibody
Company: GamaMabs Pharma (France) Mayo Clinic (USA - MN)
Therapeutic area: Cancer - Oncology
Type agreement: collaboration
Action mechanism: 3C23K monoclonal antibody is GamaMabs’ lead project. It targets Anti-Mullerian Human Receptor 2 (AMHRII/MISIIR) in ovarian cancer.
Disease: ovarian cancer
Details: * On November 27, 2014, GamaMabs Pharma announced the initiation of a collaborative study with Mayo Clinic, Rochester (MN-USA) on its 3C23K monoclonal antibody targeting AMHRII/MISIIR, with Dr. William A. Cliby, M.D, Department of Gynecologic Oncology, and Drs. John Weroha, M.D. and Paul Haluska M.D., Ph.D., Department of Oncology, as its investigators. The two entities will study the “Efficacy of GamaMabs’ 3C23K Monoclonal Antibody in Ovarian Cancer Patient-Derived Xenografts”, and will leverage Mayo Clinic’s large panel of ovarian cancer PDX and Dr. Cliby’s knowledge of AMHRII/MISIIR in this setting. In 2008, Mayo Clinic researchers J. Bakkum-Gamez, W. Cliby et al. published in Gynecologic Oncology the largest study to date on Müllerian inhibiting substance type II receptor (MISIIR) “MISIIR: A novel tissue-specific target expressed by gynecologic cancers”. This study reports that MISIIR/AMHRII is highly expressed by a wide variety of gynecologic cancers, including cancers currently without effective systemic therapies.
Financial terms:
Latest news:
